Fulcrum Therapeutics FULC
$ 4.55
-2.78%
Quarterly report 2024-Q3
added 11-13-2024
Fulcrum Therapeutics Balance Sheet 2011-2024 | FULC
Annual Balance Sheet Fulcrum Therapeutics
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-14.7 M | -21.7 M | - | - | - | -72.8 M | -407 K | - | - | - | - | - | - |
Long Term Debt |
8.63 M | 10.8 M | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
2.19 M | 2.6 M | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 5.54 M | 233 K | - | - | - | - | - | - |
Total Current Liabilities |
13.7 M | 16.7 M | 19.2 M | 26.7 M | 12.1 M | - | - | - | - | - | - | - | - |
Total Liabilities |
22.5 M | 27.7 M | 23.5 M | 34.4 M | 23.3 M | 9.77 M | 3.02 M | - | - | - | - | - | - |
Deferred Revenue |
- | 934 K | 4.71 M | 14.9 M | 3.99 M | - | - | - | - | - | - | - | - |
Retained Earnings |
-510 M | -412 M | -302 M | -222 M | -151 M | -68.1 M | -35.5 M | - | - | - | - | - | - |
Total Assets |
258 M | 227 M | 235 M | 130 M | 110 M | 85.8 M | 4.34 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
25.6 M | 35.1 M | 35.4 M | 57.1 M | 96.7 M | - | - | - | - | - | - | - | - |
Book Value |
235 M | 199 M | 212 M | 95.2 M | 87.2 M | 76 M | 1.32 M | - | - | - | - | - | - |
Total Shareholders Equity |
235 M | 199 M | 212 M | 95.2 M | 87.2 M | -63.7 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Fulcrum Therapeutics
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
7.01 M | 7.57 M | 8.1 M | 8.63 M | 9.14 M | 9.65 M | 10.1 M | 10.8 M | 11.5 M | 12.2 M | 12.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
21.7 M | 20.5 M | 19 M | 22.5 M | 23.4 M | 24.9 M | 24.9 M | 27.7 M | 26.4 M | 34.5 M | 31.1 M | 23.5 M | 24.9 M | 27 M | 28.7 M | 34.4 M | 34.4 M | 34.4 M | 34.4 M | 23.3 M | 23.3 M | 23.3 M | 23.3 M | 9.77 M | 9.77 M | 9.77 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | 334 K | 513 K | 737 K | 934 K | 1.39 M | 1.78 M | 2.92 M | 4.71 M | 6.13 M | 9.9 M | 12.1 M | 14.9 M | 14.9 M | 14.9 M | 14.9 M | 3.99 M | - | 3.99 M | 3.99 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-503 M | -481 M | -537 M | -510 M | -485 M | -461 M | -437 M | -412 M | -386 M | -362 M | -328 M | -302 M | -279 M | -258 M | -239 M | -222 M | -222 M | -222 M | -222 M | -151 M | -151 M | -151 M | -151 M | -68.1 M | -68.1 M | -68.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
279 M | 294 M | 233 M | 258 M | 279 M | 300 M | 321 M | 227 M | 248 M | 195 M | 220 M | 235 M | 256 M | 138 M | 156 M | 130 M | 130 M | 130 M | 130 M | 110 M | 110 M | 110 M | 110 M | 85.8 M | 85.8 M | 85.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
72.6 M | 86.7 M | 39.9 M | 25.6 M | 30.1 M | 34 M | 34.7 M | 35.1 M | 90.9 M | 40.2 M | 33.3 M | 35.4 M | 65.5 M | 56.8 M | 101 M | 57.1 M | 57.1 M | 57.1 M | 57.1 M | 96.7 M | 96.7 M | 96.7 M | 96.7 M | 72.8 M | 72.8 M | 72.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
257 M | 274 M | 214 M | 235 M | 255 M | 275 M | 296 M | 199 M | 221 M | 161 M | 189 M | 212 M | 231 M | 111 M | 128 M | 95.2 M | 95.2 M | 95.2 M | 95.2 M | 87.2 M | 87.2 M | 87.2 M | 87.2 M | 76 M | 76 M | 76 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
257 M | 274 M | 214 M | 235 M | 255 M | 275 M | 296 M | 199 M | 221 M | 161 M | 189 M | 212 M | 231 M | 111 M | 128 M | 95.2 M | 95.2 M | 95.2 M | 95.2 M | 87.2 M | 87.2 M | 87.2 M | 87.2 M | -63.7 M | -63.7 M | -63.7 M | -39.8 M | -33.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency